Pleuropulmonary disease due to pergolide use for restless legs syndrome

被引：45

作者：

Danoff, SK

Grasso, ME

Terry, PB

Flynn, JA

机构：

[1] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21287 USA

[2] Johns Hopkins Univ, Sch Med, Dept Internal Med, Baltimore, MD 21287 USA

[3] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD 21287 USA

[4] Johns Hopkins Univ, Sch Med, Div Mol & Clin Rheumatol, Program Outpatient Educ Med, Baltimore, MD 21287 USA

[5] Credit Suisse First Boston, Hlth Care Investment Banking, New York, NY USA

来源：

CHEST | 2001年 / 120卷 / 01期

关键词：

Parkinson's disease; pergolide; pleuropulmonary fibrosis; restless legs syndrome;

D O I：

10.1378/chest.120.1.313

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Pergolide is an ergot-derived dopamine agonist used in Parkinson's disease and, increasingly, in restless legs syndrome. We report a patient with a 2.5-year history of weight loss, pleuropulmonary fibrosis, and exudative pleural effusion that developed insidiously while taking this medication. The extensive and invasive workup that preceded the diagnosis highlights the difficulty in attributing such a process to a drug reaction. This is the second report of such a reaction to pergolide, which is one of the increasing number of ergot-derived compounds in common clinical use.

引用

页码：313 / 316

页数：4

共 8 条

[1] FIBROTIC DISORDERS ASSOCIATED WITH METHYSERGIDE THERAPY FOR HEADACHE [J].